Please login to the form below

Not currently logged in
Email:
Password:

olaratumab

This page shows the latest olaratumab news and features for those working in and with pharma, biotech and healthcare.

EMA says Lilly’s Lartruvo should not be prescribed

EMA says Lilly’s Lartruvo should not be prescribed

Lilly claimed EMA approval for Lartruvo (olaratumab) for the first-line treatment of advanced soft tissue sarcoma (STS) in 2016, when it became the first new drug for patients with the

Latest news

  • Lilly bags EU approval for cancer treatment Lartruvo Lilly bags EU approval for cancer treatment Lartruvo

    Dr Sue Mahony, president of Lilly Oncology, said: “With this decision, olaratumab is now authorised for use in the EU, offering a new treatment option for soft tissue sarcoma patients in

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with doxorubicin chemotherapy in STS patients who cannot be cured using surgery or radiotherapy, and who have a form

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    The EMA panel gave a green light to a conditional approval of Lartruvo (olaratumab), used in combination with doxorubicin chemotherapy, for advanced STS patients who cannot be treated with surgery or ... Olaratumab is also under regulatory review in the

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Top projects include PDGF inhibitor olaratumab, which was granted priority review by the FDA earlier this month for soft tissue sarcoma, and CDK4/6 inhibitor abemaciclib for advanced breast cancer and ... Olaratumab will see its first marketing

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics